Interleukin Patents (Class 424/85.2)
-
Patent number: 9017654Abstract: The present invention relates to a pharmaceutical preparation, comprising at least one Toll-like receptor ligand and at least one peptide. The invention also relates to the use of such a pharmaceutical preparation and to a vaccination method.Type: GrantFiled: October 6, 2005Date of Patent: April 28, 2015Assignee: Johannes-Gutenberg-Universitaet MainzInventors: Hansjoerg Schild, Tobias Warger, Markus Radsak, Gerd Rechtsteiner
-
Publication number: 20150110737Abstract: The invention is directed to a method of preparing B-cells that produce interleukin-10 (IL-10), or IL-10 per se, which comprises contacting one or more B-cells ex vivo with an isolated interleukin-35 (IL-35) protein, and culturing the one or more B-cells under conditions to provide one or more B-cells that produce IL-10. The invention also is directed to a method of suppressing the proliferation of lymphocytes in vitro or in vivo by contacting lymphocytes with an isolated IL-35 protein. The invention further is directed to a method of suppressing autoimmunity in a mammal by administering to the mammal an IL-35 protein or IL-10-producing B-cells.Type: ApplicationFiled: April 11, 2013Publication date: April 23, 2015Inventors: Charles Emeka Egwuagu, Ren-Xi Wang, Cheng-rong Yu
-
Publication number: 20150110739Abstract: The present application relates to stem cells isolated from various sources within the body of a patient or of a healthy donor and identified by the presence of the interleukin 12 (IL-12) receptor. The present application also provides methods for making and for using the stem cells.Type: ApplicationFiled: August 26, 2014Publication date: April 23, 2015Applicant: NEUMEDICINES, INC.Inventor: Lena A. BASILE
-
Publication number: 20150110740Abstract: The present disclosure provides compositions and methods for efficient and effective protein delivery in vitro and in vivo. In some aspects, proteins are reversibly crosslinked to each other and/or modified with functional groups and protected from protease degradation by a polymer-based or silica-based nanoshell.Type: ApplicationFiled: September 26, 2014Publication date: April 23, 2015Applicant: Massachusetts Institute of TechnologyInventors: Li Tang, Darrell J. Irvine
-
Publication number: 20150110736Abstract: An embodiment of the present invention is a method for subjecting a hematopoetic cell to a JAK/STAT inhibitor, determining the activity of gain-of-function mutations of a Jak family kinase, determining the expression levels and activity of JAK/STAT regulatory proteins, correlating the expression levels and the activity of JAK/STAT regulatory proteins with the activity of gain-of-function mutations of a Jak family kinase and with a response to the JAK/STAT inhibitor, and then classifying the cells. A further embodiment of the invention includes determining the clinical outcome based on the cell classification, determining a method of treatment, determining dosing and scheduling of at least one of the JAK/STAT inhibitors or other compounds.Type: ApplicationFiled: June 3, 2014Publication date: April 23, 2015Applicant: Nodality, Inc.Inventors: Wendy J. FANTL, Alessandra CESANO, Todd COVEY
-
Publication number: 20150110735Abstract: A centrifugal mixing device can include a shaft assembly that is operably coupled to a motor such that the motor rotates the shaft assembly about a first axis. The devices can further include a turret that is rotatably coupled to the shaft assembly such that the turret rotates about the first axis relative to the shaft assembly. The turret can include a first support, a first canister rotatably coupled to the first support such that the first canister rotates about a second axis, and a second canister rotatably coupled to the first support such that the second canister rotates about a third axis. The turret is configured to rotate about the first axis in a first rotational direction and each of the first and second canisters is configured to rotate about the second and third axes, respectively, in a second rotational direction that is opposite the first rotational direction.Type: ApplicationFiled: October 22, 2013Publication date: April 23, 2015Inventor: Steven Hoffman
-
Publication number: 20150110738Abstract: The present invention is directed to generating suppressor cells by treating naive T cells with a suppressor-inducing composition such as anti-CD3, anti-CD28, IL-2, TGF-?, or some combination thereof. Such suppressor cells are administered to patients to prevent or treat immune disorders and are allogeneic to the patient.Type: ApplicationFiled: May 2, 2013Publication date: April 23, 2015Inventor: David Horwitz
-
Patent number: 9011833Abstract: The invention relates to new formulations of compounds having activity against HCV-associated disorders, new combinations, new methods of treatment and their use in therapy.Type: GrantFiled: October 7, 2011Date of Patent: April 21, 2015Assignee: Novartis AGInventors: Sudhakar Devidasrao Garad, Anasuya Ashok Ghosh, Jay Parthiban Lakshman, Lipa Shah, Radha Vippagunta
-
Publication number: 20150104413Abstract: This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a WT-1-expressing cancer, comprising peptides derived from the WT-1 protein.Type: ApplicationFiled: January 14, 2013Publication date: April 16, 2015Applicant: MEMORIAL SLOAN KETTERING CANCER CENTERInventors: Richard J. O'Reilly, Ekaterina Doubrovina, Annamalai Selvakumar
-
Patent number: 9005600Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13R?2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.Type: GrantFiled: December 18, 2012Date of Patent: April 14, 2015Assignee: Wake Forest University Health SciencesInventors: Waldemar Debinski, Hetal Pandya, Denise Gibo
-
Patent number: 9005599Abstract: The invention provides methods of preventing or treating diseases or disorders caused by biological agents or chemical agents in a subject (e.g., a mammal, such as a human) by administering genetically modified human umbilical cord perivascular cells.Type: GrantFiled: April 20, 2009Date of Patent: April 14, 2015Assignee: Tissue Regeneration Therapeutics Inc.Inventors: Jane Elizabeth Ennis, Jeffrey Donald Turner, John Edward Davies
-
Publication number: 20150098925Abstract: The methods and systems of the present invention provide for an expression vector containing a disease-specific promoter linked to a gene encoding a therapeutic agent, such as a protein, microRNA, siRNA or other therapeutical molecule, e.g., other oligonucletide. A variety of different promoters may be used with the present invention, provided that the promoter preferentially expresses the gene linked to it at the site of the disease and not more globally within the body. The disease-specific promoter may be the promoter of the LOX1 gene. The therapeutic agent may be Interleukin 10 (IL10).Type: ApplicationFiled: October 7, 2014Publication date: April 9, 2015Inventor: Maurizio Chiriva-Internati
-
Publication number: 20150093356Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.Type: ApplicationFiled: December 11, 2014Publication date: April 2, 2015Inventor: Connie ERICKSON-MILLER
-
Publication number: 20150093357Abstract: The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example IL-15 (SEQ ID NO: 5, 6), IL-2 (SEQ ID NO: 10, 12) or combinations of both, and an interleukin receptor polypeptide portion, for example IL-15Ra (SEQ ID NO: 7, 8), IL-2Ra (SEQ ID NO: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, SCID, AIDS, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or Lupus. The therapeutic complex of the invention surprisingly demonstrates increased half-life, and efficacy in vivo.Type: ApplicationFiled: December 11, 2014Publication date: April 2, 2015Applicant: UNIVERSITY OF CONNECTICUTInventors: Leo Lefrancois, Thomas A. Stoklasek
-
Publication number: 20150093355Abstract: The invention provides a method for the treatment of Ph+ leukemia in a patient comprising administering to the patient (i) a BCR-ABL tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on Ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of Ph+ leukemia in a patient; and a composition for the treatment of Ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii). In some embodiments, the tyrosine kinase inhibitor is or is not imatinib; or is selected from the group consisting of dasatinib, nilotinib, bosutinib, axitinib, cediranib, crizotinib, damnacanthal, gefitinib, lapatinib, lestaurtinib, neratinib, semaxanib, sunitinib, toceranib, tyrphostins, vandetanib, vatalanib, INNO-406, AP24534, XL228, PHA-739358, MK-0457, SGX393 and DC2036; or is selected from the group consisting of dasatinib and nilotinib.Type: ApplicationFiled: October 17, 2014Publication date: April 2, 2015Applicant: CSL LIMITEDInventors: Devendra Keshaorao HIWASE, Timothy Peter HUGHES, Angel Francisco LOPEZ, Gino Luigi VAIRO
-
Patent number: 8992904Abstract: The present invention is directed to therapeutic methods and compositions, especially subcutaneous and intravenous composition using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.Type: GrantFiled: November 24, 2010Date of Patent: March 31, 2015Assignee: Alderbio Holdings LLCInventors: Jeffrey T. L. Smith, John A. Latham, Mark Litton, Randall Schatzman
-
Publication number: 20150086505Abstract: Provided are methods of producing mono- and di-pegylated IL-10.Type: ApplicationFiled: February 18, 2014Publication date: March 26, 2015Applicant: MERCK SHARP & DOHME CORPORATIONInventors: Steven J. Blaisdell, Collette M. Cutler, Brittany C. Paporello, Alexandre Ambrogelly
-
Publication number: 20150086508Abstract: The invention disclosed herein relates to the field of epidermal repair and skin innate immunity. More particularly, the invention concerns the use of a mix of cytokines to inhibit keratinocyte differentiation, activate skin innate immunity, increase the expression of anti-microbial peptides, and improve epidermal repair. In particular, the invention concerns compositions comprising at least IL-17, TNF? and OSM that can be formulated for topical administration for cosmetic or dermatologic use.Type: ApplicationFiled: September 29, 2014Publication date: March 26, 2015Inventors: Jean-Claude Lecron, Hughes Gascan, Franck Morel, Sylvie Chevalier, Francois-Xavier Bernard, Katia Boniface, Caroline Diveau
-
Publication number: 20150086507Abstract: Methods to improve hematopoiesis and increase white blood cell counts in subjects and patients using pyrimidine-based inhibitors of Bruton's tyrosine kinase (Btk) are disclosed.Type: ApplicationFiled: April 11, 2013Publication date: March 26, 2015Inventors: Raquel IZUMI, Francisco SALVA, Ahmed HAMDY
-
Publication number: 20150086506Abstract: Methods and compositions are provided for the persistent modification of cell membranes with exogenous proteins so as to alter the function of the cell to achieve effects similar to those of gene therapy, without the introduction of exogenous DNA. DNA sequences, the proteins and polypeptides embodying these sequences are disclosed for modulating the immune system. The modulations include down-regulation, up-regulation and apoptosis.Type: ApplicationFiled: May 19, 2014Publication date: March 26, 2015Applicant: University of Louisville Research Foundation, Inc.Inventor: Haval Shirwan
-
Publication number: 20150079025Abstract: Featured is T cell receptor complexes designed to redirect the immune system against various diseases. The T cell receptor complexes of the invention have been engineered to recognize target antigen in a functionally bispecific nature. Fusion protein complexes and protein conjugate complexes are comprised of high affinity antigen-specific TCR and biologically active proteins and/or effector molecules. Also featured is methods of production of T cell receptor fusion and conjugate complexes as well as therapeutic compositions for use of the complexes.Type: ApplicationFiled: June 12, 2014Publication date: March 19, 2015Inventors: Hing C. Wong, Peter Rhode, Xiaoyun Zhu
-
Publication number: 20150079026Abstract: The absence of regulatory T cells (Treg) may underlie disorders including but not limited to autoimmunity, dermatitis, periodontitis and even transplant rejection. Enhancing local numbers of Treg through in situ Treg expansion or induction is contemplated herein as a treatment option for these disorders. Current methods for in vivo Treg expansion are not Treg specific and are associated with many adverse side-effects. The data presented herein provides in vitro testing of a Treg-inducing microparticle providing a predictable controlled release for combinations of cytokines and drugs (e.g., IL-2, TGF-?, and/or rapamycin) resulting in targeted Treg migration. These controlled release microparticles are also capable of inducing FoxP3+ Treg in human cells in vitro suggesting that these compositions be developed into an in vivo Treg induction and expansion therapy.Type: ApplicationFiled: January 22, 2013Publication date: March 19, 2015Inventors: Steven R. Little, Giorgio Raimondi, Angus W. Thomson, Siddharth Jhunjhunwala
-
Publication number: 20150079027Abstract: Improved protocols that enhance the effect of immunotherapy against tumors are described. The protocol involves enhancing the immune response to an antitumor vaccine by maximizing the ability of T cells induced by the vaccine to extravasate into the tumor and also to modulate the effect of Tregs so that the effectiveness of the vaccine is not undermined. The former effect is achieved by radiation at the site of the tumor or lesions. This latter effect is achieved by an initial depletion of Tregs in combination with modulating their effect during the vaccine administration protocol.Type: ApplicationFiled: March 26, 2013Publication date: March 19, 2015Applicant: DENDRITHERAPEUTICS, INC.Inventor: Anthony E. Maida, III
-
Publication number: 20150080940Abstract: Described are embolization devices which carry M1 macrophage promoting agents and/or M2 macrophage inhibiting agents, as well as methods for their manufacture and use. An illustrative embolization device of the disclosure comprises an embolic body and one or more M1 macrophage promoting agents and/or M2 macrophage inhibiting agents carried by a surface of the embolic body. In certain embodiments the embolic body of the present disclosure comprises an embolic coil or an embolic bead.Type: ApplicationFiled: August 27, 2014Publication date: March 19, 2015Inventor: Colleen Gemborys
-
Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof
Publication number: 20150079028Abstract: Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.Type: ApplicationFiled: August 5, 2013Publication date: March 19, 2015Applicant: SUNSHINE LAKE PHARMA CO., LTDInventors: Yingjun Zhang, Jaincun Zhang, Hongming Xie, Qingyun Ren, Yumei Tan, Huichao Luo -
Publication number: 20150079029Abstract: The present invention relates to a method of inhibiting angiogenesis in a biological system. The method includes administering to the biological system an effective amount of a steroid saponin.Type: ApplicationFiled: August 27, 2014Publication date: March 19, 2015Inventors: Michael John Story, Kenneth Michael Wayte
-
Publication number: 20150079023Abstract: The present invention is directed to the combination therapy of an afucosylated antibody specifically binding to a tumor-antigen with human IL-15 for the treatment of cancer.Type: ApplicationFiled: April 16, 2014Publication date: March 19, 2015Applicant: ROCHE GLYCART AGInventors: CHRISTIAN KLEIN, EMILIE LAPREVOTTE, ANNE QUILLET-MARY
-
Publication number: 20150079030Abstract: An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid.Type: ApplicationFiled: September 5, 2014Publication date: March 19, 2015Applicant: GlaxoSmithKline LLCInventor: Stephen Moore
-
Publication number: 20150079031Abstract: Provided are methods of treatment for tumors. In particular, methods are provided for use of a chemically modified IL-10 to treat tumors.Type: ApplicationFiled: September 12, 2014Publication date: March 19, 2015Inventors: Martin Oft, Catherine Sheppard, John Brian Mumm, Lingling Wu
-
Publication number: 20150079024Abstract: The inventive subject matter relates to novel methods for modulating an immune response in an animal, which comprises administering to said animal an effective amount of an agent that increases IL-27R/WSX-1 activity. Further, the inventive subject matter relates to pharmaceutical compositions comprising an effective amount of an agent that increases IL-27R/WSX-1 activity.Type: ApplicationFiled: April 18, 2014Publication date: March 19, 2015Applicant: The Trustees of the University of PennsylvaniaInventors: Christopher A. Hunter, Alejandro Villarino
-
Publication number: 20150079032Abstract: The invention relates to therapy and methods of applying the therapy to a patient. The invention includes the introduction of immature dendritic cells into the patient and the introduction of anti-TNF antibody into the patient. The immature dendritic cells are introduced intratumorally and/or through vessel and the anti-TNF antibody is introduced intratumorally and/or through vessel and/or subcutaneously. The immature dendritic cells can be formed by collecting monocyte cells from the patient and culturing the cells in a culture medium. The invention can be effective to regress, reduce or eliminate tumor cells in tumor tissue of the patients, including metastasized tumors. Further, the treatment of the invention is effective in the absence of conventional therapy, such as radiotherapy and chemotherapy.Type: ApplicationFiled: November 21, 2014Publication date: March 19, 2015Applicant: HASUMI INTERNATIONAL RESEARCH FOUNDATIONInventor: KENICHIRO HASUMI
-
Patent number: 8980244Abstract: The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.Type: GrantFiled: April 15, 2013Date of Patent: March 17, 2015Assignees: Ben-Gurion University of the Negev Research and Development Authority, Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd.Inventors: Ofer Mandelboim, Angel Porgador, Yaakov Naparstek, Chamutal Gur
-
Publication number: 20150071877Abstract: A method for preparing a bioactive composition containing conditioned cell culture medium is disclosed. The method comprises culturing cells of two or more eukaryotic cell line to form conditioned culture media, separating the cultured cells from the conditioned culture media, and combining conditioned culture media to form a bioactive composition. Novel bioactive compositions, formulations and their use in treating of a variety of diseases and health conditions are also disclosed.Type: ApplicationFiled: November 12, 2014Publication date: March 12, 2015Inventors: Greg Maguire, Peter Friedman
-
Publication number: 20150071875Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: ApplicationFiled: May 21, 2014Publication date: March 12, 2015Inventors: Jochen G. Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Edward Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M. Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W. Warner, Angela Myles, John Gawain Elvin, Alexander Robert Duncan, Elaine Joy Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Du Fou
-
Publication number: 20150071874Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.Type: ApplicationFiled: September 12, 2013Publication date: March 12, 2015Applicant: Biosuccess Biotech Co. Ltd.Inventors: Zheng Tao Han, Hung-Fong Chen
-
Publication number: 20150071876Abstract: A combined measles-malaria vaccine containing different attenuated recombinant measles-malaria vectors comprising a heterologous nucleic acid encoding several Plasmodium falciparum antigens is described. Preferably, it relates to viral vectors that comprise nucleic acids encoding the circumsporozoite (CS) protein of P. falciparum, the merozoite surface protein 1 (MSP-1) of P. falciparum, and its derivatives (p-42; p-83-30-38) in its glycosylated and secreted forms, and apical membrane antigen1 (AMA1) of P. falciparum, in its anchored or secreted form. The viral vector stems from an attenuated measles virus, based on a strain that is used as a vaccine and is efficient in delivering the gene of interest and that binds to and infects the relevant immune cells efficiently.Type: ApplicationFiled: September 15, 2014Publication date: March 12, 2015Applicant: CADILA HEALTHCARE LIMITEDInventors: Reinhard GLUECK, Agata FAZIO, Viviana GIANINO, Martin A. BILLETER
-
Publication number: 20150071987Abstract: In some embodiments, described herein is a method of tumor treatment or tumor vaccination. The method generally comprises applying to a human being in need thereof a tumor therapeutic composition or tumor vaccine defined herein. The tumor therapeutic composition or tumor vaccine can be produced by protein transfer of glycosyl-phosphatidylinositol (GPI)-anchored immunostimulatory or costimulatory molecules.Type: ApplicationFiled: February 1, 2013Publication date: March 12, 2015Applicant: EMORY UNIVERSITYInventor: Periasamy Selvaraj
-
Patent number: 8974776Abstract: Novel biodegradable compositions are disclosed. The biodegradable compositions include at least one hydroxyl-terminated component and at least one bioactive peptide in a linear chain. The compositions may be utilized as medical devices including drug delivery devices, tissue adhesives and/or sealants.Type: GrantFiled: May 14, 2008Date of Patent: March 10, 2015Assignee: Covidien LPInventors: Joshua B. Stopek, Brian Cuevas
-
Publication number: 20150064133Abstract: The present disclosure provides a composition comprising a bioactive fraction derived from a platelet concentrate, methods of making the bioactive fraction, and culture medium supplemented with the bioactive fraction. Preferred bioactive fractions have relatively low fibrinogen concentrations while retaining native growth factors in beneficial amounts and ratios.Type: ApplicationFiled: August 27, 2014Publication date: March 5, 2015Inventors: Erik J. Woods, Christopher Taylor
-
Publication number: 20150064265Abstract: A “nanolipogel” is a delivery vehicle including one or more lipid layer surrounding a hydrogel core, which may include an absorbent such as a cyclodextrin or ion-exchange resin. Nanolipogels can be constructed so as to incorporate a variety of different chemical entities that can subsequently be released in a controlled fashion. These different incorporated chemical entities can differ dramatically with respect to size and composition. Nanolipogels have been constructed to contain co-encapsulated proteins as well as small hydrophobic drugs within the interior of the lipid bilayer. Agents incorporated within nanolipogels can be released into the milieu in a controlled fashion, for example, nanolipogels provide a means of achieving simultaneous sustained release of agents that differ widely in chemical composition and molecular weight. Additionally, nanolipogels can favorably modulate biodistribution.Type: ApplicationFiled: April 12, 2013Publication date: March 5, 2015Inventors: Tarek M. Fahmy, Eric Stern, Richard A. Flavell, Jason Park, Alyssa Siefert, Stephen H. Wrzesinski
-
Patent number: 8968716Abstract: Disclosed herein are an in situ-forming, bioadhesive hydrogel and the medical uses thereof. Being formed by in situ crosslinking through an enzymatic reaction, the hydrogel has an advantage over conventional bioadhesive hydrogels in terms of biocompatibility. In addition, the in situ-forming bioadhesive hydrogel has excellent biocompatibility and mechanical strength and has excellent tissue adhesiveness thanks to modification with/without dopa derivatives. The hydrogel finds a variety of applications in the biomedical field, including bioadhesives or hemostats, implant substances for tissue regeneration and augmentation, carriers for delivering biologically active materials or drugs, etc.Type: GrantFiled: September 2, 2010Date of Patent: March 3, 2015Assignee: Ajou University Industry-Academic Cooperation FoundationInventors: Ki-Dong Park, Yoon-Ki Joung, Kyung-Min Park, Eu-Gene Lih
-
Publication number: 20150056160Abstract: An invention relating to therapeutic pharmacological agents and methods to chemically induce intracellular hyperthermia and/or free radicals for the diagnosis and treatment of infections, malignancy and other medical conditions. The invention relates to a process and composition for the diagnosis or killing of cancer cells and inactivation of susceptible bacterial, parasitic, fungal, and viral pathogens by chemically generating heat, and/or free radicals and/or hyperthermia—inducible immunogenic determinants by using mitochondrial uncoupling agents, especially 2,4 dinitrophenol and, their conjugates, either alone or in combination with other drugs, hormones, cytokines and radiation.Type: ApplicationFiled: February 24, 2014Publication date: February 26, 2015Inventors: Nicholas Bachynsky, Woodie Roy
-
Publication number: 20150056162Abstract: Variant IL-13 polypeptides are provided, which are engineered to have one or more of the following properties: (a) altered affinity for IL-13R?2, relative to the native human IL-13 protein; (b) altered affinity for IL-13R?1 relative to the native human IL-13 protein; (c) a disruption in the binding site for IL-4R? relative to the native human IL-13 protein.Type: ApplicationFiled: January 25, 2013Publication date: February 26, 2015Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Kenan Christopher Garcia, Ignacio Moraga Gonzalez
-
Publication number: 20150056161Abstract: This invention provides a method of treating a disorder of a subject's heart involving loss of cardiomyocytes which comprises administering to the subject a composition comprising an amount of a human stromal derived factor-1 and an amount of a human granulocyte-colony stimulating factor, the composition being administered in an amount effective to cause proliferation of cardiomyocytes within the subject's heart so as to thereby treat the disorder. This invention also provides a method of treating a subject suffering from a disorder of a tissue involving loss and/or apoptosis of cells of the tissue which comprises administering to the subject a composition comprising an amount of an agent which induces phosphorylation and/or activation of protein kinase B, or an agent which induces phosphorylation and/or activation of an extracellular signal-regulated protein kinase, or an agent which induces activation of CXCR4.Type: ApplicationFiled: March 4, 2014Publication date: February 26, 2015Applicant: The Trustees of Columbia University in the City of New YorkInventor: Silviu Itescu
-
Publication number: 20150056163Abstract: The present invention relates to methods for preventing or treating Human Immunodeficiency Virus (HIV) infection, inflammatory conditions, and graft-versus-host-disease (GVHD) in a subject. Therapeutic compositions of the present invention comprise Leukocidin E (LukE) and/or D proteins or polypeptides. The invention further relates to methods of treating Staphylococcus aureus infection by administering a composition comprising a CCR5 antagonist or any molecule that blocks LukE/D interaction with CCR5+ cells in an amount effective to treat the S. aureus infection in the subject.Type: ApplicationFiled: August 25, 2014Publication date: February 26, 2015Inventors: Victor J. Torres, Derya Unutmaz, Francis Alonzo, III
-
Patent number: 8961950Abstract: Low doses of IL-2 are administered locally and neo-adjuvantly to patients with early stages of the disease. This will result in local high concentrations of IL-2 within the relevant tumor draining lymph nodes. Patients with only early stages of disease will be more responsive to immunotherapy with the expectation of improved survival of patients compared to current therapy standards.Type: GrantFiled: August 10, 2011Date of Patent: February 24, 2015Inventors: Ulrik Mouritzen, Christiane Voit
-
Publication number: 20150050238Abstract: The present invention relates to the treatment of osteoarthritis and pain using IL-1? and IL-1? binding proteins, including anti-IL-1? and anti-IL-1? antibodies and engineered multivalent and multispecific IL-1? and IL-1? binding proteins.Type: ApplicationFiled: July 29, 2014Publication date: February 19, 2015Inventor: Rajesh V. KAMATH
-
Publication number: 20150051441Abstract: The present invention relates to methods of and compositions comprising cytokines for, improving the success rate of embryo implantation and the success rate of pregnancy rates in females, by providing an immunopermissive uterine environment prior to insemination or implantation of embryos. The methods of the present invention are used to make the uterus more receptive or less hostile to, for example, transferred embryos, sperm or other allografted tissue.Type: ApplicationFiled: August 12, 2014Publication date: February 19, 2015Inventors: Nadia Gopichandran, Nicolas Michel Orsi, David Andrew Brooke
-
Publication number: 20150050215Abstract: The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.Type: ApplicationFiled: September 14, 2012Publication date: February 19, 2015Applicant: Axon Neuroscience SEInventors: Michal Novak, Eva Kontseková, Branislav Kovácech, Norbert Zilka
-
Publication number: 20150050332Abstract: In various embodiments, the present invention describes materials and methods for the local reprogramming of cells in a location where the treatment is applied. The invention can be used to replace lost cells or to restore function to tissue damaged due to disease, injury or genetic defect. In various embodiments, the treatment includes a semisolid hydrogel embedded with liposomes. The liposomes can contain an effector molecule or molecules. When phagocytic cells such as monocytes infiltrate the hydrogel, they encounter the liposomes and incorporate the liposomes carrying the effector molecules into the cells. In some embodiments, the effector molecules can be genetic material encoding the expression of specific proteins such as transcription factors, the expression of which can initiate the reprogramming of the cells. In other embodiments, the effector molecules can induce angiogenesis. In other embodiments, the effector molecules are tumor antigens.Type: ApplicationFiled: November 3, 2014Publication date: February 19, 2015Inventor: Shai Yehoshua Schubert